[one]{.smallcaps} [of]{.smallcaps} [the]{.smallcaps} [most]{.smallcaps} [notable]{.smallcaps} characteristics of the inflammatory response during sepsis in both humans and animal experimental models is its deleterious effect on microcirculation. These microcirculatory blood flow alterations are mainly characterized by decreased functional capillary density and increased heterogeneity leading to blood flow misdistribution ([@B1], [@B10], [@B18], [@B23], [@B34]), tissue hypoperfusion, and the subsequent development of multiple organ dysfunction ([@B48]). It was initially proposed that a mismatch of O~2~ demand to supply could impair O~2~ utilization by tissues ([@B26], [@B40], [@B41]). This notion was reinforced by mathematical models suggesting that heterogeneity of O~2~ delivery could decrease tissue O~2~ extraction ([@B49]). In fact, evidence coming from ex vivo intestinal tissue in endotoxemic pigs revealed the importance of increased heterogeneity in microcirculatory transit times on the impairment of O~2~ extraction ([@B21]). The nature of such experiments, however, hindered the temporal variations of heterogeneity of flow during the development of, and resuscitation from, septic shock. Other experimental data suggested that the misdistribution of microvascular blood flow leads to O~2~ capillary extraction derangements during sepsis ([@B11]) such that heterogeneous flow cessation of individual capillaries could determine O~2~ supply dependence during the most severe cases of septic shock ([@B16]).

The gastrointestinal tract is particularly prone to being affected during low flow states ([@B9], [@B44]), and it has been hypothesized that improvement in splanchnic perfusion might prevent the progression of shock. Thus, some synthetic catecholamines capable of increasing cardiac output and O~2~ delivery have been used aiming at reverting tissue hypoperfusion. Its impact on splanchnic circulation remains controversial, however, with apparent favorable ([@B3], [@B33], [@B37], [@B39], [@B47]), unchanged ([@B35]), or even negative effects ([@B2], [@B13]) on both splanchnic arterial flow and total microcirculatory blood flow at the intestinal mucosa. Despite these different effects on macro and total microvascular blood flow, some vasoactive amines and inodilators have been shown to promote favorable effects on intestinal oxygenation ([@B14]), although mucosal oxygenation might, in turn, be dissociated from splanchnic O~2~ delivery when some of them are infused ([@B33], [@B43]), which suggests the predominance of distributive alterations over total reductions in microcirculatory blood flow. Notably, microvascular blood flow distribution could potentially be modified by inodilators during septic shock ([@B7], [@B42]), although its effect during human septic shock remains controversial ([@B12], [@B18]).

We therefore proposed to evaluate the dynamic variations of the heterogeneity of blood flow distribution at the intestinal mucosa and its relation with the regional O~2~ extraction ratio during the development and resuscitation of septic shock in a model of fecal peritonitis subjected to hemodynamic goal-directed fluid resuscitation and randomly assigned to receive, or not, a low-fixed dose of dobutamine, hypothesizing that variations in microcirculatory heterogeneity are closely related to changes in regional O~2~ extraction independent of macrohemodynamic changes.

METHODS {#sec1}
=======

 {#sec1-1}

### Animal preparation. {#sec1-1-1}

Our institutional Animal Research Committee approved the present study (Res. 001--12). Fifteen female Landrace pigs (35--42 kg) were kept fasting for a 12-h period, with free access to water. After this preconditioning period, they were initially sedated with intramuscular injections of ketamine (5--10 mg/kg) and xylazine (0.1 mg/kg). Next, a venous access (Insyte Autoguard infusion therapy system) was inserted in the ear to facilitate the administration of medication and fluids. After an intravenous dose of propofol (2--4 mg/kg) and fentanyl (5 µg/kg), an endotracheal tube and mainstream volumetric capnography were placed (Infinity EtCO~2~ + respiratory mechanics module; Dräger Medical Systems). The animals were connected to mechanical ventilation (Servo 900C; Siemens, Solna, Sweden) in assist control mode, with a tidal volume of 12 ml/kg, and the volume per minute was adjusted to maintain arterial P[co]{.smallcaps}~2~ at 38 ± 5 mmHg. Anesthesia was maintained throughout the experiment with midazolam (3--5 µg·kg^−1^·min^−1^), fentanyl (0.03--0.05 µg·kg^−1^·min^−1^), and propofol (50 µg·kg^−1^·min^−1^). Muscular paralysis was provided with pancuronium bromide (5 µg·kg^−1^·min^−1^) during the entire experiment. Neck vessels were accessed by direct dissection, and catheters were inserted in the carotid artery (Single lumen central venous 7-Fr catheter; Arrow International) to monitor arterial pressure and to enable blood sampling while the left internal jugular vein was used for resuscitation fluid infusion. We also placed a continuous-cardiac-output (CCO) pulmonary artery catheter (7.5-Fr, Edwards Swan-Ganz CCO; Baxter Edwards Critical Care, Irvine, CA) through the right internal jugular vein to measure pulmonary arterial pressures and continuous cardiac output and to enable the withdrawal of mixed-venous blood samples. Core temperature was continuously monitored using a thermistor in the pulmonary artery catheter, and external heating was used to maintain a central temperature of 36.5 ± 1°C. Continuous electrocardiographic, pulsioximetry, and invasive pressures were also monitored throughout the experiment (Drägger Infinity Vista XL; Drägger Medical System, Lübeck, Germany).

A midline laparotomy was performed, and a gas-tonometer catheter (TRIP Tonometry Catheter, 8-Fr; Tonometrics Division, Instrumentarium, Helsinki, Finland) was placed in the jejunal lumen at 50 cm beyond the Treitz angle for local tissue CO~2~ and pH~i~ measurements. A double-lumen catheter (2-lumen central venous 7-Fr gauge catheter; Arrow International) was inserted in the superior mesenteric vein through the splenic vein after splenectomy and local constriction with epinephrine, ensuring its position under echographic guide. An infusion with 0.9% saline solution at 5 ml/h through this catheter was provided during the experiment to ensure its permeability. Surgical cystostomy was also undertaken to monitor urinary output. A jejunum loop was exteriorized through the midline incision, and a small segment was opened along its antimesenteric border using an electrocautery. After baseline measurements, cecal ligation and puncture with 16-gauge needle followed by peritoneal contamination (1.5 g/kg of feces) were performed in experimental models (not for sham animals). After careful hemostasis, the abdominal contents were returned to the cavity, and the abdomen was closed, leaving out the jejunostomy loop, which was then covered with moistened compresses and an anti-adherent bag to avoid heat and fluid loss.

### General monitoring. {#sec1-1-2}

Mean arterial pressure was monitored throughout the experiment, and pulse pressure variations (dPP) were calculated during the respiratory cycle as: PPinsp -- PPexp/(PPinsp + PPexp/2) (Drägger Infinity Vista XL; Drägger Medical System). Mean pulmonary artery, central venous, and pulmonary arterial occlusion pressures were measured at the end of expiration and referenced to the midchest level. Cardiac output was continuously measured using the thermodilution principle with a thermal filament on the pulmonary artery catheter (Vigilance; Baxter Edwards Critical Care). A mainstream capnography and respiratory module (Dräger Medical Systems) was used to measure airway and alveolar dead-space fraction, end-tidal CO~2~, and complete respiratory mechanics.

### Calculation of CO~2~ and O~2~ variables. {#sec1-1-3}

Simultaneous arterial (a), mixed-venous ($\overline{\text{v}}$), and mesenteric-venous (mes) blood samples were withdrawn at each measurement time point to determine blood gases, hemoglobin, and lactate concentrations (The Alere Epoc blood analysis system; Alere, Waltham, MA). Concurrent mucosal jejunal CO~2~ was measured by gas tonometry (Tonocap, Datex-Ohmeda; Tonometrics Division, Instrumentarium) as described elsewhere ([@B4]). O~2~ and CO~2~ parameters were calculated according to the following formulas:$$\text{C}\text{a}_{\text{O}_{2}} = (\text{Hg} \times \text{S}\text{a}_{\text{O}_{2}} \times 1.34) + (\text{P}\text{a}_{\text{O}_{2}} \times 0.003)$$ $$\text{C}\text{v}_{\text{O}_{2}} = (\text{Hg} \times \text{S}\text{v}_{\text{O}_{2}} \times 1.34) + (\text{P}\text{v}_{\text{O}_{2}} \times 0.003)$$ $$\text{Da-}\text{v}_{\text{O}_{2}} = \text{C}\text{a}_{\text{O}_{2}} - \text{C}\text{v}_{\text{O}_{2}}$$ $$\text{D}\text{o}_{2} = \text{C}\text{a}_{\text{O}_{2}} \times \text{CO}$$ $$\overset{․}{V}\text{o}_{2} = \text{C}\text{a}_{\text{O}_{2}} - \text{C}\text{v}_{\text{O}_{2}}) \times \text{CO}$$ $$\text{E}\text{R}_{\text{O}_{2}} = (\text{C}\text{a}_{\text{O}_{2}} - \text{C}\text{v}_{\text{O}_{2}})/\text{C}\text{a}_{\text{O}_{2}}$$ $$\text{mes-E}\text{R}_{\text{O}_{2}} = (\text{C}\text{a}_{\text{O}_{2}} - \text{Cvme}\text{s}_{\text{O}_{2}})/\text{C}\text{a}_{\text{O}_{2}}$$ $$\text{Mixed\ venous-to-arterial}{\, CO}_{2}\text{ difference }(\text{P}\overline{\text{v}}\text{-}\text{a}_{\text{C}\text{O}_{2}}) = \text{P}{\overline{\text{v}}}_{\text{C}\text{O}_{2}} - \text{P}\text{a}_{\text{C}\text{O}_{2}}$$ $$\text{Mesenteric\ venous-to-arterial }{CO}_{2}\text{ difference }(\text{Pmes-}\text{a}_{\text{C}\text{O}_{2}}) = \text{Cvme}\text{s}_{\text{C}\text{O}_{2}} - \text{P}\text{a}_{\text{C}\text{O}_{2}}$$ $$\text{Jejunum\ mucosal-to-arterial }{CO}_{2}\text{ difference }(\text{Ptis-}\text{a}_{\text{C}\text{O}_{2}}) = \text{Pti}\text{s}_{\text{C}\text{O}_{2}} - \text{P}\text{a}_{\text{C}\text{O}_{2}}$$where $\text{C}\text{a}_{\text{O}_{2}}$ and $\text{C}\text{v}_{\text{O}_{2}}$ are the arterial and venous O~2~ content, respectively; $\text{P}\text{a}_{\text{O}}{}_{{}_{2}}$ and $\text{Pv}_{\text{O}_{2}}$ represent the arterial and venous partial pressures, respectively, and CO represents cardiac output. $\text{E}\text{R}_{\text{O}_{2}}$ and $\text{mes-E}\text{R}_{\text{O}_{2}}$ represent the total and mesenteric O~2~ extraction ratio, respectively.

### Microcirculatory measurements. {#sec1-1-4}

We used the Sidestream dark-field (SDF) technique (Micro Scan; MicroVision Medical, Amsterdam, The Netherlands) to explore microcirculation at each measurement time point ([Fig. 1](#F0001){ref-type="fig"}). In all cases, images were acquired by the same operator (Ospina-Tascón) who remained blinded as to dobutamine or placebo use both during acquisition and the semiquantitative analysis of the video sequences. After careful removal of intestinal secretions by warm water and gentle aspiration, the SDF device was directly applied through the surgically prepared jejunostomy and on the antimesenteric opposite serosa surface to evaluate jejunal villi and serosa microcirculation, respectively, covering an intestinal segment of at least 15 cm. Meanwhile, sublingual microcirculation was assessed by SDF soft application to the lateral side of the tongue covering an area approximately of 4--6 cm from the tip of tongue after gentle removal of secretions with gauze. At each measurement time point ([Fig. 1](#F0001){ref-type="fig"}), five video sequences of 20 s each were acquired at five different points from the respective mucosa or adjacent serosa areas using a videocard (MicroVideo; Pinnacle System, Mountain Views, CA). These sequences of video were stored under a random number and later evaluated by two investigators blind to the origin of such sequences (Quiñones and Ospina-Tascón). For this semiquantitative analysis, we counted the number of villi in each image, and individual villi microcirculation was classified according to its predominant blood flow as either normal perfused (continuous blood flow), hypoperfused (intermittent or sluggish blood flow), or nonperfused (stopped blood flow). Thus, we calculated the percentage of villi with normal-perfused capillaries in each video sequence to finally report the mean of the five video sequences acquired at each time point. Meanwhile, for serosa and sublingual microcirculation evaluation, we used a cutoff value of 20 μm to classify the vessels as large or small. Microvessels with continuous flow were considered as normal, whereas sluggish, intermittent, and stopped flows were considered as abnormal. Serosa and sublingual microcirculatory blood flow were evaluated according to the consensus for the evaluation of microcirculation ([@B8]), and we also calculated the proportion of small-perfused vessels (\<20 μm diameter), the heterogeneity index (HI), the total vascular density (all vessels), and the functional capillary density (i.e., the number of vessels \<20 μm of diameter adequately perfused, per area unit). The intra- and interobserver variabilities were determined by using five sequences analyzed five times at 8-wk intervals by two observers (Quiñones and Ospina-Tascón). We calculated the intraobserver and interobserver coefficient of variability for both the total number of vessels and the proportion of perfused vessels.

![Experimental protocol. 1, Presurgical period (acclimatization-adaptation period, initial sedation, muscular paralysis, endotracheal intubation); 2, surgical period (catheters insertion: carotid and pulmonary artery, internal jugular vein, mesenteric vein; laparotomy: jejunal tonometer insertion; cystostomy; jejunal ostomy preparation); 3, serial measurements \[arterial, mixed-venous, and mesenteric-venous blood sampling; jejunal tonometric measurements; acquisition of microcirculation images (jejunal mucosa, jejunal serosa, sublingual mucosa)\]. BL, baseline; TS, time of shock; T2H, 2 h after starting resuscitation; T6H, 6 h after starting resuscitation.](zdg0051721800001){#F0001}

### Experimental protocol. {#sec1-1-5}

The experimental protocol is outlined in [Fig. 1](#F0001){ref-type="fig"}. After the initial preparation, a stabilization period of 30 min was ensured, and then baseline measurements (BL) were performed. Animals were subsequently randomly allocated to the dobutamine (*n* = 6), placebo (*n* = 6), or sham (*n* = 3) group. An independent laboratory staff member (not participating as an author in the present manuscript) was in charge of the randomization and preparation of these experimental infusions. Cecal ligation and puncture, followed by peritoneal contamination, was performed only in the dobutamine and placebo models. All animals received intravenous lactate Ringer fixed infusion at 3 ml/kg throughout the experiment. When hypotension was developed and it was not corrected by successive crystalloid boluses (at least 30 ml/kg), norepinephrine (NE) infusion was started and titrated to maintain mean arterial pressure (MAP) \>65 mmHg. Once the NE dose remained stable for at least 30 min, time shock (TS) was declared, and a new set of measurements were obtained. After this point, resuscitation was conducted using successive fluid loads of crystalloid (at 10 ml/kg) guided by dynamic predictors of fluid responsiveness to optimize cardiac output. Concomitantly, fixed doses of dobutamine (5 µg·kg^−1^·min^−1^) or placebo (0.9% saline solution at isovolumetric dose) were infused throughout the experiment. A new set of measurements was performed at 2 (T2H) and 6 (T6H) h afterward. Sham animals were subjected to identical monitoring as the experimental groups. The timing used for measurements in the sham group was referenced to the median time required from peritonitis induction to fulfilling shock definition during the preexperimental standardization phase. Thus, T12H in the sham group was selected as the matched time for TS, so new measurements were performed 2 and 6 h later, thus constituting T14H and T18H, i.e., the equivalent to T2H and T6H in the experimental models ([Fig. 1](#F0001){ref-type="fig"}). Euthanasia was performed at the end of the experiment using Euthanex according to the local regulations for animal research.

### Statistical analysis. {#sec1-1-6}

Data are reported as medians and interquartile ranges. After testing the sphericity assumptions, time, time-group interactions, and intergroup differences for the experimental groups were evaluated using the repeated-measures analysis of variance, with a subsequent Student-Newman-Keuls (SNK) test for multiple comparisons. The relationship between microcirculatory blood flow variables, lactate levels, and mesenteric O~2~ extraction ratio was tested using the Spearman Rho test, and the coefficient of determination (*R*^2^) was calculated to establish the strength of such associations. A *P* value ≤ 0.05 (2-tailed) was considered significant.

RESULTS {#sec2}
=======

 {#sec2-1}

### Systemic hemodynamics and O~2~ transport. {#sec2-1-1}

General hemodynamics, blood gases, and fluids/vasopressor use are presented in [Table 1](#T1){ref-type="table"}. Hypodynamic shock was developed 12 (10--14) h after the induction of peritonitis in the dobutamine (D group) and placebo (P group) models, with similar falls in cardiac output \[91.2 (84.8--94.1) vs. 75.0 (68.2--95.1) ml·kg^−1^·min^−1^ for P and D group, respectively; *P* = 0.21\] and systemic O~2~ delivery \[13.4 (12.5--15.1) vs. 13.9 (10.9--15.0) ml·kg^−1^·min^−1^ for P and D groups, respectively; *P* = 0.88\] ([Table 1](#T1){ref-type="table"}). Subsequently, cardiac output and systemic O~2~ delivery exhibited a similar improvement in the D and P groups at T2H and T6H (repeated-measurements analysis, *P* = 0.86 and 0.84 for time × group interactions, and *P* = 0.51 and 0.56 for intergroup differences for CO and D[o]{.smallcaps}~2~, respectively) ([Table 1](#T1){ref-type="table"}).

###### 

Hemodynamics, blood gases, and O~2~/CO~2~ parameters

                                                                                                                                                                                                                Intragroup Difference         
  ------------------------------------------------------ ---------------------- ---------------------- --------------------------------------------------- --------------------------------------------------- ----------------------- ------ ------
  *Hemodynamic variables*                                                                                                                                                                                                                     
  HR, beats/min                                                                                                                                                                                                                               
      Placebo                                                 90 (81--130)          154 (131--180)                       155 (153--168)                                      164 (132--174)                             0.01            0.99   0.34
      Dobutamine                                              97 (87--128)          187 (113--205)                       156 (142--189)                                      172 (146--197)                                                   
      Sham                                                   146 (140--151)         108 (96--120)                         99 (98--100)                                         70 (54--85)                                                    
  CO, ml·kg^−1^·min^−1^                                                                                                                                                                                                                       
      Placebo                                             122.9 (111.8--138.2)    91.2 (84.8--94.1)                   125.7 (120.6--138.2)                                138.2 (128.6--145.5)                         \<0.001          0.86   0.51
      Dobutamine                                          100.0 (90.9--120.0)     75.0 (68.2--95.1)                    106.8 (90.9--144.1)                                123.2 (104.5--152.7)                                                
      Sham                                                104.3 (100.0--108.6)   108.7 (108.6--108.8)                 108.7 (105.7--111.8)                                113.0 (111.8--114.3)                                                
  MAP, mmHg                                                                                                                                                                                                                                   
      Placebo                                                102 (92--114)           70 (69--77)                           71 (69--82)                                         65 (63--97)                              0.001           0.18   0.54
      Dobutamine                                             100 (88--105)           81 (77--87)                           67 (65--71)                                         77 (60--82)                                                    
      Sham                                                    97 (87--106)          100 (81--118)                        102 (100--105)                                      129 (123--135)                                                   
  CVP, mmHg                                                                                                                                                                                                                                   
      Placebo                                                 12 (7--21)-            13 (10--15)                           13 (11--18)                                         14 (12--22)                              0.15            0.98   0.29
      Dobutamine                                               10 (5--14)             9 (8--10)                            11 (10--12)                                         12 (10--15)                                                    
      Sham                                                    14 (13--15)            15 (13--16)                           13 (12--15)                                         15 (11--18)                                                    
  Temperature, °C                                                                                                                                                                                                                             
      Placebo                                              35.8 (34.3--36.4)      38.1 (35.1--38.3)                     37.8 (34.3--38.1)                                   36.8 (33.8--38.4)                           0.02            0.76   0.38
      Dobutamine                                           35.9 (34.9--37.0)      38.2 (37.1--39.8)                     37.0 (36.4--37.6)                                   36.6 (36.3--37.3)                                                 
      Sham                                                 34.7 (33.8--35.6)      34.6 (33.5--35.7)                      35.1 (34.1--36)                                    34.5 (33.1--35.6)                                                 
  *Blood gases, lactate, and O~2~ variables*                                                                                                                                                                                                  
  pH (arterial)                                                                                                                                                                                                                               
      Placebo                                              7.38 (7.37--7.40)      7.34 (7.28--7.36)                     7.31 (7.24--7.41)                                   7.20 (7.10--7.42)                           0.002           0.11   0.55
      Dobutamine                                           7.38 (7.38--7.39)      7.27 (7.21--7.28)                     7.20 (7.14--7.26)                                   7.29 (7.27--7.32)                                                 
      Sham                                                 7.39 (7.38--7.40)      7.42 (7.40--7.43)                     7.41 (7.39--7.42)                                   7.42 (7.40--7.45)                                                 
  $\text{P}\text{a}_{\text{CO}}{}_{{}_{2}}$, mmHg                                                                                                                                                                                             
      Placebo                                              34.6 (32.9--37.5)      40.1 (35.0--40.2)                     37.6 (36.2--42.4)                                   38.6 (37.2--40.3)                           0.01            0.15   0.83
      Dobutamine                                           29.9 (29.5--33.2)      41.7 (36.3--50.5)                     42.2 (41.6--46.3)                                   39.1 (36.0--39.8)                                                 
      Sham                                                 34.1 (33.6--34.5)      34.7 (34.2--35.1)                     34.7 (34.2--35.1)                                   35.0 (34.6--35.3)                                                 
  $\text{Pv-}\text{a}_{\text{C}\text{O}_{2}}$, mmHg                                                                                                                                                                                           
      Placebo                                                3.0 (2.7--4.2)       12.0 (11.0--15.5)                     11.7 (11.6--16.0)                    9.9 (9.3--14.1)[\*](#T1F1){ref-type="table-fn"}           \<0.001          0.06   0.05
      Dobutamine                                             4.9 (4.5--5.1)       13.6 (12.1--16.6)                      9.2 (6.6--10.2)                                     6.5 (4.7--7.5)                                                   
      Sham                                                   3.5 (3.3--3.7)         4.1 (3.7--4.4)                       4.0 (3.7--4.4)                                      4.4 (4.0--4.7)                                                   
  $\text{Pvmes-}\text{a}_{\text{C}\text{O}_{2}}$, mmHg                                                                                                                                                                                        
      Placebo                                                5.8 (3.7--6.8)       18.4 (18.2--18.9)     17.6 (11.0--22.4)[\*](#T1F1){ref-type="table-fn"}   19.2 (9.3--19.2)[\*](#T1F1){ref-type="table-fn"}           \<0.001          0.01   0.05
      Dobutamine                                             5.8 (3.8--6.4)       20.3 (17.5--23.4)                      7.0 (5.7--11.1)                                     5.1 (3.7--5.9)                                                   
      Sham                                                   6.3 (4.8--7.7)         3.6 (3.5--3.7)                       3.6 (3.5--3.7)                                      4.6 (2.7--6.5)                                                   
  $\text{Ptis-}\text{a}_{\text{C}\text{O}_{2}}$, mmHg                                                                                                                                                                                         
      Placebo                                               10.4 (6.4--11.1)      32.0 (25.9--34.0)                     23.4 (23.3--30.6)                   33.4 (24.7--34.8)[\*](#T1F1){ref-type="table-fn"}          \<0.001          0.01   0.01
      Dobutamine                                            11.1 (4.5--14.0)      30.7 (28.5--34.7)                     20.4 (19.4--24.3)                                   16.0 (14.2--16.9)                                                 
      Sham                                                  9.5 (8.5--10.4)         6.4 (3.9--8.8)                       6.8 (5.2--8.4)                                     13.1 (12.4--13.7)                                                 
  Lactate-art, mmol/l                                                                                                                                                                                                                         
      Placebo                                                1.8 (1.7--2.3)         7.4 (7.1--7.8)       8.3 (6.7--9.9)[\*](#T1F1){ref-type="table-fn"}      8.9 (8.4--9.3)[\*](#T1F1){ref-type="table-fn"}            \<0.001          0.03   0.02
      Dobutamine                                             1.9 (1.9--2.1)         7.5 (7.5--8.1)                       4.4 (3.8--7.4)                                      2.3 (2.1--3.9)                                                   
      Sham                                                   1.4 (1.1--1.7)         0.9 (0.8--1.0)                       1.1 (1.0--1.2)                                      1.2 (0.7--1.8)                                                   
  Lactate-mes, mmol/l                                                                                                                                                                                                                         
      Placebo                                                2.6 (2.0--2.6)         8.2 (7.9--8.5)                       8.9 (5.6--12.2)                     7.3 (4.6--10.3)[\*](#T1F1){ref-type="table-fn"}           \<0.001          0.02   0.03
      Dobutamine                                             2.1 (1.8--2.2)         7.6 (7.3--8.2)                       6.4 (3.8--7.1)                                      4.2 (3.4--4.8)                                                   
      Sham                                                   1.6 (1.2--2.0)         1.0 (1.0--1.1)                       1.2 (1.1--1.3)                                      1.1 (0.8--1.4)                                                   
  $\text{S}\text{V}_{\text{O}_{2}}$, %                                                                                                                                                                                                        
      Placebo                                              67.6 (61.4--70.3)      68.8 (55.6--72.5)                     73.7 (73.4--74.8)                                   77.5 (71.4--77.8)                           0.14            0.19   0.22
      Dobutamine                                           62.5 (53.0--71.1)      62.0 (61.2--71.7)                     66.1 (62.6--66.4)                                   65.8 (64.5--66.0)                                                 
      Sham                                                 71.4 (69.8--71.9)      72.7 (68.3--77.1)                     65.9 (65.8--66.0)                                   77.1 (74.5--79.6)                                                 
  $\text{Sv}\text{mes}_{\text{O}_{2}}$, %                                                                                                                                                                                                     
      Placebo                                              74.4 (72.3--75.0)      34.4 (32.5--36.0)     38.4 (35.1--52.7)[\*](#T1F1){ref-type="table-fn"}   52.2 (48.9--57.2)[\*](#T1F1){ref-type="table-fn"}          \<0.001          0.08   0.03
      Dobutamine                                           75.5 (74.9--78.0)      32.0 (30.5--32.5)                     58.7 (45.0--60.5)                                   67.5 (64.4--68.4)                                                 
      Sham                                                 73.9 (72.3--75.6)      67.5 (66.1--68.8)                     68.5 (67.0--70.0)                                   70.8 (69.9--71.6)                                                 
  D[o]{.smallcaps}~2~, ml·kg^−1^·min^−1^                                                                                                                                                                                                      
      Placebo                                              17.0 (14.1--18.9)      13.4 (12.5--15.1)                     17.1 (15.8--21.9)                                   18.4 (17.7--18.7)                           0.01            0.84   0.56
      Dobutamine                                           14.5 (13.5--17.3)      13.9 (10.9--15.0)                     18.6 (12.2--19.3)                                   18.0 (15.4--20.0)                                                 
      Sham                                                 12.5 (12.4--12.5)      12.9 (12.3--13.5)                     13.0 (12.3--13.6)                                   13.0 (12.1--13.8)                                                 
  V̇[o]{.smallcaps}~2~, ml·kg^−1^·min^−1^                                                                                                                                                                                                      
      Placebo                                                5.9 (4.4--7.0)         5.8 (4.9--6.2)                       8.2 (7.8--8.3)                                      8.9 (7.1--8.9)                             0.003           0.38   0.18
      Dobutamine                                             5.6 (4.7--5.7)         6.0 (4.7--6.5)                       7.3 (6.3--7.9)                                      6.2 (6.1--7.1)                                                   
      Sham                                                   4.2 (4.0--4.4)         4.7 (4.7--4.8)                       4.5 (4.2--4.8)                                      4.7 (4.4--5.0)                                                   
  Systemic $\text{E}\text{R}_{\text{O}_{2}}$                                                                                                                                                                                                  
      Placebo                                              0.34 (0.30--0.40)      0.42 (0.37--0.46)                     0.47 (0.41--0.48)                                   0.48 (0.40--0.55)                           0.02            0.20   0.40
      Dobutamine                                           0.36 (0.35--0.39)      0.40 (0.39--0.47)                     0.41 (0.40--0.41)                                   0.40 (0.36--0.40)                                                 
      Sham                                                 0.33 (0.32--0.35)      0.37 (0.35--0.38)                     0.35 (0.34--0.35)                                   0.36 (0.36--0.37)                                                 
  Mesenteric $\text{E}\text{R}_{\text{O}_{2}}$                                                                                                                                                                                                
      Placebo                                              0.27 (0.27--0.29)      0.65 (0.64--0.65)     0.62 (0.47--0.63)[\*](#T1F1){ref-type="table-fn"}   0.44 (0.44--0.46)[\*](#T1F1){ref-type="table-fn"}          \<0.001          0.04   0.02
      Dobutamine                                           0.26 (0.23--0.26)      0.68 (0.64--0.68)                     0.37 (0.37--0.49)                                   0.32 (0.25--0.35)                                                 
      Sham                                                 0.27 (0.25--0.28)      0.33 (0.32--0.35)                     0.32 (0.30--0.34)                                   0.31 (0.29--0.32)                                                 
  *Fluids/vasopressors*                                                                                                                                                                                                                       
  Cumulative fluids, ml                                                                                                                                                                                                                       
      Placebo                                                                    2,013 (1,977--2,237)                 2,810 (2,643--2,877)                                3,285 (3,218--3,339)                         \<0.001          0.90   0.85
      Dobutamine                                                                 2,190 (2,112--2,376)                 2,792 (2,790--3,116)                                3,248 (3,150--3,644)                                                
      Sham                                                                        1259 (1200--1290)                   1,559 (1,500--1,600)                                1,973 (1,950--1,998)                                                
  Norepinephrine, µg·kg^−1^·min^−1^                                                                                                                                                                                                           
      Placebo                                                                     0.52 (0.42--0.53)                     0.28 (0.25--0.30)                                   0.20 (0.18--0.24)                          \<0.001          0.94   0.44
      Dobutamine                                                                  0.49 (0.45--0.58)                     0.26 (0.24--0.32)                                   0.20 (0.20--0.22)                                                 
      Sham                                                                                                                                                                                                                                    

All data are presented as medians (25--75 percentiles); *n* = 6 (dobutamine), 6 (placebo), and 3 (sham) animals in each group. TS, time shock; T2H, 2 h after starting resuscitation; T6H, 6 h after starting resuscitation; HR, heart rate; CO, cardiac output; MAP, mean arterial pressure; CVP, central venous pressure; pH, arterial pH; $\text{P}\text{a}_{\text{CO}}{}_{{}_{2}}$, arterial CO~2~ partial pressure; $\text{Pv-}\text{a}_{\text{C}\text{O}_{2}}$, mixed venous-to-arterial CO~2~ difference; $\text{Pvmes-}\text{a}_{\text{C}\text{O}_{2}}$, mesenteric venous-to-arterial CO~2~ difference; $\text{Ptis-}\text{a}_{\text{C}\text{O}_{2}}$, tissue (jejunal mucosa)-to-arterial CO~2~ difference; Lactate art, arterial lactate; Lactate mes, mesenteric lactate; $\text{S}\text{V}_{\text{O}_{2}}$, mixed-venous O~2~ saturation; $\text{Sv}\text{mes}_{\text{O}_{2}}$, mesenteric-venous O~2~ saturation; D[o]{.smallcaps}~2~, systemic O~2~ delivery; V̇[o]{.smallcaps}~2~, systemic O~2~ consumption; systemic $\text{E}\text{R}_{\text{O}_{2}}$, systemic O~2~ extraction ratio; mesenteric $\text{E}\text{R}_{\text{O}_{2}}$, mesenteric O~2~ extraction ratio.

SNK test, *P* \< 0.05 for P vs. D group.

### Microcirculatory blood flow. {#sec2-1-2}

Complete intestinal and sublingual microcirculatory parameters are presented in [Table 2](#T2){ref-type="table"}. The time course of the proportion of jejunal villi with normal-perfused vessels (%Villi-PPV) was significantly different between groups (repeated-measures analysis, *P* = 0.02 for time × group interactions and *P* = 0.04 for intergroup differences; SNK test, *P* \< 0.05 for P vs. D at T2H and T6H) ([Fig. 2](#F0002){ref-type="fig"}). The percentage of small vessels perfused at the sublingual mucosa (SL-PPV) exhibited similar variations to villi-PPV, with significant improvement in the D group, although without attaining complete normalization at the end of the experiment ([Fig. 2](#F0002){ref-type="fig"}). An excess of stopped vessels at the intestinal mucosa explained the decreasing %villi-PPV at TS in the P and D groups ([Fig. 3](#F0003){ref-type="fig"}). Thereafter, the D group exhibited significant and progressive improvement of microcirculation at the jejunal-villi, moving from stopped to intermittent and continuous flows, thus improving functional capillary density and decreasing microvascular blood flow heterogeneity ([Fig. 3](#F0003){ref-type="fig"}), although without attaining complete normalization at T6H. Dynamic changes in the proportion of capillaries with stopped flow were significantly related to variations in $\text{mes-E}\text{R}_{\text{O}_{2}}$ (Spearman Rho test, *R*^2^ = 0.83, *P* \< 0.001) and lactate levels (Spearman Rho test, *R*^2^ = 0.72, *P* \< 0.001) ([Fig. 4](#F0004){ref-type="fig"}). Meanwhile, jejunal serosa and sublingual mucosa exhibited similar variations to those observed at the jejunal-villi, with severely decreased PPV at TS, followed by significant recovery in the D group ([Table 2](#T2){ref-type="table"}). Such alterations were paralleled by decreased functional capillary density and increasing microvascular blood flow heterogeneity at both the jejunal serosa and sublingual mucosa ([Table 2](#T2){ref-type="table"}). Examples of the intestinal microcirculatory blood flow images captured by the SDF technique during the development and resuscitation phase of the experiment are presented as supplemental data \[baseline (Supplemental Videos 1A--1B); TS (Supplemental Videos 2A--2B), and dobutamine at T6H (Supplemental Videos 3A--3B) (Supplemental videos for this article can be found on the journal website.)\]. Our coefficient of variability of the determination of one video sequence ranged from 2.9 to 6.4% (intraobserver) and from 3.8 to 6.2% (interobserver) for the total number of vessels and from 1.9 to 4.5% (intraobserver) and from 3.4 to 6.8% (interobserver) for the proportion of perfused vessels (all sizes).

###### 

Microcirculatory blood flow parameters

                                                                                                                                                                             Intragroup Difference         
  ------------------------ --------------------- ------------------- -------------------------------------------------- --------------------------------------------------- ----------------------- ------ ------
  Villi-PPV, %                                                                                                                                                                                             
      Placebo               100.0 (97.5--100.0)    0.0 (0.0--6.8)     6.9 (0.0--28.9)[\*](#T2F1){ref-type="table-fn"}    18.8 (17.0--31.8)[\*](#T2F1){ref-type="table-fn"}          \<0.001          0.02   0.04
      Dobutamine            98.5 (98.0--100.0)     0.0 (0.0--13.9)                   48.9 (16.7--76.5)                                   79.0 (67.4--79.6)                                                 
      Sham                   97.5 (96.5--98.5)    97.5 (96.5--98.5)                                                                      94.8 (94.6--95.0)                                                 
  Ser-PPV, %                                                                                                                                                                                               
      Placebo                97.4 (90.1--99.7)    31.2 (16.7--37.8)                  34.3 (22.6--49.2)                   32.7 (6.5--58.7)[\*](#T2F1){ref-type="table-fn"}           \<0.001          0.01   0.04
      Dobutamine            100.0 (87.9--100.0)   16.7 (0.0--20.8)                    45.4 (7.4--45.7)                                   85.7 (75.7--91.5)                                                 
      Sham                   68.7 (67.8--69.6)    89.0 (88.5--89.4)                                                                     97.8 (95.6--100.0)                                                 
  Ser-FCD, vessels/mm^2^                                                                                                                                                                                   
      Placebo                 6.8 (5.6--7.9)       1.3 (0.4--2.2)                      2.0 (1.1--2.3)                     2.5 (2.1--2.7)[\*](#T2F1){ref-type="table-fn"}            \<0.001          0.12   0.03
      Dobutamine              6.3 (5.9--8.8)       0.9 (0.0--1.2)                      2.1 (0.4--2.4)                                     5.2 (3.5--5.6)                                                   
      Sham                    5.5 (5.3--5.6)       6.8 (6.7--6.8)                                                                         6.3 (5.2--7.4)                                                   
  Ser-HI                                                                                                                                                                                                   
      Placebo                 0.2 (0.0--0.2)       1.5 (0.8--2.0)      1.0 (1.0--1.5)[\*](#T2F1){ref-type="table-fn"}     2.0 (1.5--2.6)[\*](#T2F1){ref-type="table-fn"}             0.03            0.12   0.03
      Dobutamine              0.0 (0.0--0.3)       2.0 (0.0--2.8)                      0.5 (0.2--0.6)                                     0.1 (0.0--0.3)                                                   
      Sham                    0.7 (0.3--1.1)       0.3 (0.2--0.4)                                                                         0.3 (0.0--0.6)                                                   
  SL-PPV, %                                                                                                                                                                                                
      Placebo                87.0 (85.9--95.7)    31.8 (21.2--32.1)   34.5 (8.2--67.2)[\*](#T2F1){ref-type="table-fn"}   22.8 (22.7--67.0)[\*](#T2F1){ref-type="table-fn"}          \<0.001          0.02   0.01
      Dobutamine             86.2 (81.0--95.1)    20.7 (13.2--29.9)                  68.3 (47.5--71.1)                                   69.1 (58.2--70.3)                                                 
      Sham                   83.3 (79.5--87.2)    88.3 (86.1--90.4)                                                                      97.6 (96.3--98.9)                                                 
  SL-FCD, vessels/mm^2^                                                                                                                                                                                    
      Placebo                 7.0 (6.9--7.1)       2.5 (1.6--3.0)      2.8 (0.5--3.8)[\*](#T2F1){ref-type="table-fn"}     2.1 (1.9--4.5)[\*](#T2F1){ref-type="table-fn"}            \<0.001          0.11   0.04
      Dobutamine              6.5 (6.0--6.9)       1.7 (0.8--2.2)                      4.6 (4.0--5.7)                                     4.6 (4.5--5.7)                                                   
      Sham                    7.6 (7.4--7.8)       9.1 (8.9--9.3)                                                                        10.9 (10.9--11.0)                                                 
  SL-HI                                                                                                                                                                                                    
      Placebo                 0.3 (0.1--0.4)       2.1 (2.0--3.1)                      1.5 (0.8--2.3)                     1.7 (1.1--2.5)[\*](#T2F1){ref-type="table-fn"}            \<0.001          0.02   0.04
      Dobutamine              0.8 (0.8--0.9)       1.5 (1.5--2.6)                      0.9 (0.8--1.2)                                     0.9 (0.4--1.0)                                                   
      Sham                    0.4 (0.3--0.4)       0.3 (0.2--0.3)                                                                         0.1 (0.1--0.1)                                                   

All data are presented as medians (25--75 percentiles); *n* = 6 (dobutamine), 6 (placebo), and 3 (sham) animals in each group. Villi-PPV, proportion of jejunal-villi with well-perfused vessels; Ser-PPV, percentage of small vessels perfused at jejunal serosa; Ser-FCD, functional capillary density at jejunal serosa; Ser-HI, heterogeneity index at jejunal serosa; SL-PPV, percentage of small vessels perfused at sublingual mucosa; SL-FCD, functional capillary density at sublingual mucosa; SL-HI, heterogeneity index at sublingual mucosa.

SNK test, *P* \< 0.05 for P vs. D group.

![Time course of variations in the percentage of villi with predominantly well-perfused small vessels (%villi-PPV) and the percentage of small vessels perfused at sublingual mucosa (SL-PPV). *A*: %villi-PPV: repeated-measurements analysis, *P* \< 0.001 for time effect; *P* = 0.02 for time-group interactions; *P* = 0.04 for intergroup differences. Student-Newman-Keuls (SNK) test, *P* \< 0.05 for sham vs. P and sham vs. D groups at TS, T2H, and T6H; SNK test, *P* \< 0.05 for P vs. D at T2H and T6H. *B*: SL-PPV: repeated-measures analysis, *P* \< 0.001 for time effect; *P* = 0.02 for time-group interaction; *P* = 0.01 for intergroup differences. SNK test, *P* \< 0.05 for sham vs. P and sham vs. D groups at TS, T2H, and T6H; *P* \< 0.05 for P vs. D at T2H and T6H). No. of animals is as follows: dobutamine (*n* = 6), placebo (*n* = 6), and sham (*n* = 3).](zdg0051721800002){#F0002}

![Predominant type of microvascular flow in the jejunal villi at each measurement time. Percentage distribution of predominant microvascular blood flow in jejunal villi capillaries at baseline (*A*), TS (*B*), T2H (*C*), and T6H (*D*). †*P* \< 0.05 between sham vs. dobutamine and placebo groups. \**P* \< 0.05 between dobutamine vs. placebo groups. No. of animals is as follows: dobutamine (*n* = 6), placebo (*n* = 6), and sham (*n* = 3).](zdg0051721800003){#F0003}

![Relationships between the variations of the percentage of villi with stopped capillary flow (Δvilli-stopped capillaries), mesenteric O~2~ extraction ratio (Δ$\text{mes-E}\text{R}_{\text{O}_{2}}$), and percentage changes of mesenteric lactate levels (%mes-Lactate variation). *A*: scatterplot depicting the relationships between Δvilli-stopped capillaries vs. Δ$\text{mes-E}\text{R}_{\text{O}_{2}}$. Spearman Rho test, *R*^2^ = 0.83, *P* \< 0.001. *B*: scatterplot depicting the relationships between Δvilli-stopped capillaries vs. %mes-Lactate variation. Spearman Rho test, *R*^2^ = 0.72, *P* \< 0.001. All absolute or percentage variations (Δ) were calculated as the change between actual and its immediately preceding value (*A* and *B*).](zdg0051721800004){#F0004}

### $\textit{E}\textit{R}_{\textit{O}_{2}}$ and its relationships with microcirculatory blood flow. {#sec2-1-3}

$\text{mes-E}\text{R}_{\text{O}_{2}}$ showed a significant increase in both P and D groups at TS \[0.65 (0.64--0.65) vs. 0.68 (0.64--0.68) for P and D groups, respectively; Mann-Whitney Rank sum test, *P* \> 0.05\]. Despite significant improvement in $\text{mes-E}\text{R}_{\text{O}_{2}}$ after starting resuscitation in both experimental groups, the slope of $\text{mes-E}\text{R}_{\text{O}_{2}}$ recovery was significantly steeper in the D group (repeated-measures analysis, *P* = 0.04 for time × group interaction and *P* = 0.02 for intergroup differences. SNK test, *P* \< 0.05 for sham vs. P and D at TS; *P* \< 0.05 for P vs. D at T2H and T6H) ([Fig. 5*A*](#F0005){ref-type="fig"}). Variations of villi-PPV during shock development and resuscitation depicted a very good agreement with variations in $\text{mes-E}\text{R}_{\text{O}_{2}}$ (Spearman Rho test, *R*^2^ = 0.88, *P* \< 0.001) ([Fig. 5*B*](#F0005){ref-type="fig"}).

![Time course of mesenteric O~2~ extraction ratio ($\text{mes-E}\text{R}_{\text{O}_{2}}$) and its relationships with variations in villi-PPV. *A*: time course of $\text{mes-E}\text{R}_{\text{O}_{2}}$. Repeated measurements analysis, *P* = 0.04 for time-group interactions; *P* = 0.02 for intergroup differences. \**P* \< 0.05 for P vs. D groups. *B*: scatterplot for Δ% villi-PPV vs. Δ$\text{mes-E}\text{R}_{\text{O}_{2}}$. (Spearman Rho test, *R*^2^ = 0.88, *P* \< 0.001). Δ% villi-PPV and Δ$\text{mes-E}\text{R}_{\text{O}_{2}}$ were calculated as the variation between actual and its immediately preceding value (*B*). No. of animals is as follows: dobutamine (*n* = 6), placebo (*n* = 6), and sham (*n* = 3).](zdg0051721800005){#F0005}

### Systemic, regional, and local CO~2~ to arterial differences. {#sec2-1-4}

Variations in the tissue-to-arterial CO~2~ difference ($\text{Pti-}\text{a}_{\text{C}\text{O}_{2}}$) agreed with regional changes ($\text{Pmes-}\text{a}_{\text{C}\text{O}_{2}}$) and these, in turn, with systemic venous-to-arterial CO~2~ differences ($\text{P}\overline{\text{v}}\text{-}\text{a}_{\text{C}\text{O}_{2}}$) ([Table 1](#T1){ref-type="table"}). $\text{Pti-}\text{a}_{\text{C}\text{O}_{2}}$ and $\text{Pmes-}\text{a}_{\text{C}\text{O}_{2}}$ exhibited a good agreement with villi-PPV (Spearman-Rho test, *R*^2^ = 0.69 and 0.63, respectively, *P* \< 0.001), and showed a more discrete agreement with Ser-PPV (Spearman-Rho test, *R*^2^ = 0.48 and 0.47, respectively, *P* \< 0.001). Meanwhile, mesenteric venous-arterial CO~2~ to arterial-venous O~2~ pressure differences ratio ($\text{Pvmes-}\text{a}_{\text{C}\text{O}_{2}}$/$\text{Ca}\text{-v}_{\text{O}_{2}}$ ratio) was well correlated with mesenteric lactate levels (Spearman-Rho test, *R*^2^ = 0.60, *P* \< 0.001), suggesting the appearance and reversal of anaerobic metabolism during shock development and the resuscitation phase (in the D group), respectively ([Fig. 6*A*](#F0006){ref-type="fig"}). Notably, the time course of the $\text{Pvmes-}\text{a}_{\text{C}\text{O}_{2}}$-to-$\text{Ca}\text{-v}_{\text{O}_{2}}$ ratio was significantly different in experimental groups, showing a significant decrease in the D group at T6H ([Fig. 6*B*](#F0006){ref-type="fig"}).

![Relationships between $\text{Pvmes-}\text{a}_{\text{C}\text{O}_{2}}$/$\text{Ca}\text{-vmes}_{\text{O}_{2}}$ ratios vs. mesenteric-venous lactate levels and time course of $\text{Pvmes-}\text{a}_{\text{C}\text{O}_{2}}$/$\text{Ca}\text{-vmes}_{\text{O}_{2}}$ ratios. *A*: scatterplot depicting the relationships between the mesenteric venous-arterial CO~2~ to arterial-venous O~2~ pressure differences ratio ($\text{Pvmes-}\text{a}_{\text{C}\text{O}_{2}}$/$\text{Ca}\text{-vmes}_{\text{O}_{2}}$ ratio) vs. mesenteric-venous lactate levels. Spearman Rho test, *R*^2^ = 0.60, *P* \< 0.001. *B*: time course of the mesenteric venous-arterial CO~2~ to arterial-venous O~2~ pressure differences ($\text{Pvmes-}\text{a}_{\text{C}\text{O}_{2}}$/$\text{Da}\text{-vmes}_{\text{O}_{2}}$). Repeated-measures analysis, *P* = 0.32 for time effect; *P* = 0.06 for time-group interaction; *P* = 0.05 for intergroup differences. \**P* \< 0.05 for D vs. P groups (*B*). No. of animals is as follows: dobutamine (*n* = 6), placebo (*n* = 6), and sham (*n* = 3).](zdg0051721800006){#F0006}

### Relationships between variations of lactate levels, regional O~2~ extraction ratio, and jejunal microcirculatory blood flow. {#sec2-1-5}

We observed significant increases in arterial and venous mesenteric lactate levels at TS. Models subjected to dobutamine infusion showed a significant decrease at T2H and T6H in both arterial lactate (repeated-measures analysis, *P* ≤ 0.001 for the time effect; *P* = 0.03 for time × group interaction; and *P* = 0.02 for intergroup differences; SNK test, *P* \< 0.05 for P vs. D at T2H and T6H) and venous-mesenteric lactate (repeated-measures analysis, *P* ≤0.001 for the time effect, *P* = 0.02 for time × group interaction, and *P* = 0.03 for intergroup differences; SNK test, *P* \< 0.05 for P vs. D at T2H and T6H) levels, whereas lactate levels remained high in the placebo group ([Table 1](#T1){ref-type="table"}). Variations in $\text{mes-E}\text{R}_{\text{O}_{2}}$ were well correlated with changes in both absolute venous lactate values and the percentage of variation of venous lactate (using as reference the immediately preceding value) ([Fig. 7](#F0007){ref-type="fig"}).

![Relationships between variations of Δ$\text{mes-E}\text{R}_{\text{O}_{2}}$, Δmes-Lactate, and %mes-Lactate variation. *A*: scatterplot depicting the relationships between Δ$\text{mes-E}\text{R}_{\text{O}_{2}}$ vs. Δmes-Lactate. Spearman Rho test, *R*^2^ = 0.68, *P* \< 0.001. *B*: scatterplot depicting the relationships between Δ$\text{mes-E}\text{R}_{\text{O}_{2}}$ vs. %mes-Lactate variation. Spearman Rho test, *R*^2^ = 0.86, *P* \< 0.001. All percentage or absolute variations (Δ) were calculated as the variation between actual and its immediately preceding value (*A* and *B*).](zdg0051721800007){#F0007}

DISCUSSION {#sec3}
==========

Our results suggest that variations in the distribution of intestinal microcirculatory blood flow at the jejunal-villi during the development of, and resuscitation from, septic shock are closely related to changes in regional O~2~ extraction ratios and these, in turn, to variations in mesenteric lactate levels. Although cardiac output and systemic O~2~ delivery evolved similarly in both the D and P groups, the heterogeneity of microcirculatory blood flow at the jejunal mucosa and serosa was significantly reversed after dobutamine infusion, which was accompanied by decreases in mesenteric O~2~ extraction ratio and mesenteric lactate levels.

Variations in $\text{E}\text{R}_{\text{O}_{2}}$ denote adaptive cellular responses to O~2~ availability. Indeed, experimental models during early stages of sepsis demonstrated up to a threefold increase in the capillary $\text{E}\text{R}_{\text{O}_{2}}$ in normal perfused muscle, which intuitively suggest that increases in $\text{E}\text{R}_{\text{O}_{2}}$ should reflect the maximization of such adaptation to hypoxic tissue challenges ([@B12]). However, the assumption that tissue oxygenation can be preserved by maintaining its blood supply is derived from models that presume uniformly perfused capillaries. Conversely, septic shock is characterized by increased heterogeneity of microcirculatory blood flow, which implies the presence of zones of tissue receiving an adequate perfusion through capillaries with continuous flow in close proximity with zones with no microvascular perfusion due to capillaries with stopped flow ([@B12]), which leads to inhomogeneity of O~2~ distribution and, therefore, to abnormal cellular respiration, such as has been observed using in vivo NADH videofluorimetry techniques ([@B22]). We observed a severe decline in the proportion of small vessels perfused at both the jejunal and sublingual mucosa at the time of shock with a subsequent increase in blood flow heterogeneity and decrease in functional capillary density. Such as mathematical models have suggested, heterogeneity of O~2~ delivery should respond in part for tissue O~2~ derangements in peripheral tissues ([@B49]). Indeed, experimental evidence from ex vivo intestinal pieces after endotoxin infusion suggests that the heterogeneity of gut capillary transit times is related to impairment of gut O~2~ extraction ([@B21]). However, the static concept of such experiments ([@B21]) makes it difficult to understand the relationships between microvascular blood flow heterogeneity and O~2~ utilization during the development and resuscitation of septic shock. Conversely, the dynamic nature of our experiment reveals that variations in the percentage of well-perfused capillaries at jejunal villi (villi-PPV) are closely related with dynamic changes in mesenteric $\text{E}\text{R}_{\text{O}_{2}}$ and these, in turn, with variations in mesenteric lactate values. Mathematical modeling of O~2~ demand (d[o]{.smallcaps}~2~) to O~2~ supply (q[o]{.smallcaps}~2~) distributions (d[o]{.smallcaps}~2~/q[o]{.smallcaps}~2~) demonstrates that increases in its relative dispersion lead to a nonlinear decrease in the critical O~2~ extraction ratio ([@B49]). Thus, deviations of d[o]{.smallcaps}~2~ vs. d[o]{.smallcaps}~2~/q[o]{.smallcaps}~2~ distribution "to the right" (i.e., \>1.0) suggest the appearance of anaerobic metabolism even at the same total O~2~ transport (D[o]{.smallcaps}~2~) values, i.e., attainment of anaerobic thresholds at lower critical $\text{E}\text{R}_{\text{O}_{2}}$ and D[o]{.smallcaps}~2~ values ([@B49]). In our experiment, rises in regional O~2~ extraction ratios were accompanied by increases in both total (crude) and percentage of variation in mesenteric lactate levels, which reinforces the notion that alterations in d[o]{.smallcaps}~2~/q[o]{.smallcaps}~2~ distributions attained during our experiment were enough to overcome anaerobic metabolism thresholds previously reported in experimental conditions ([@B21], [@B27], [@B28], [@B38]).

We observed an increased number of stopped vessels at the time of shock coinciding with the higher $\text{mes-E}\text{R}_{\text{O}_{2}}$ and mesenteric lactate levels. We hypothesized that increases in the proportion of capillaries with stopped blood flow could overcome the capacity of O~2~ delivery from capillaries with normal flow, thus leading to tissue O~2~ supply limitation. Thus, mesenteric-$\text{E}\text{R}_{\text{O}_{2}}$ was increased to the extent that functional capillary density declined with the subsequent widening of O~2~ diffusion distances. As a result, anaerobic metabolism was triggered, leading to increases of regional lactate levels, thus suggesting a key role for the heterogeneous stoppage of individual capillaries on abnormal O~2~ utilization during very early stages of septic shock. Previous mathematical modeling revealed that, for three forms of progressive hypoxia (anemic, stagnant, and hypoxic), critical total O~2~ transport is quite similar, as long as intercapillary distances are \<80 µm ([@B39]). Nevertheless, at higher intercapillary distances (i.e., at lower functional capillary densities), O~2~ consumption (V̇[o]{.smallcaps}~2~) becomes dependent from total O~2~ transport (D[o]{.smallcaps}~2~) for a wide range of values ([@B39]), suggesting that increments in heterogeneity of microvascular blood flow lead to d[o]{.smallcaps}~2~/q[o]{.smallcaps}~2~ mismatching (which is reflected by low critical $\text{E}\text{R}_{\text{O}_{2}}$ values), thus indicating an impairment of O~2~ extraction ability ([@B49]). In our study, models receiving dobutamine showed a gradual replacement of stopped with intermittent and normal flows, which improved the functional capillary density and led to a parallel reduction in $\text{mes-E}\text{R}_{\text{O}_{2}}$ and regional lactate levels. This phenomenon suggests that, as microvascular blood flow became more homogeneous, tissues should exhibit better d[o]{.smallcaps}~2~/q[o]{.smallcaps}~2~ distributions with the subsequent reversion of anaerobic metabolism. Some studies have proposed that the heterogeneous cessation of flow in individual capillaries could determine O~2~ supply dependence during septic shock ([@B11]), whereas mathematical modeling of this phenomenon suggests that oxygenation derangements are more severe when capillary blood flow is totally stopped than when it is intermittent ([@B16]), which also agrees with our results.

Dobutamine has shown contradictory results on macrovascular splanchnic ([@B2], [@B3], [@B13], [@B33], [@B35], [@B37], [@B39], [@B47]), total intestinal microvascular blood flow ([@B19], [@B29]), and sublingual microcirculation ([@B7], [@B12], [@B18]). Conversely, information about the effect of dobutamine on microcirculatory blood flow distribution at intestinal villi during sepsis or endotoxemia has been limited but favorable ([@B42]). Interestingly, mesenteric arterial blood flow can be relatively dissociated from microvascular blood flow ([@B46]), and misdistribution of blood flow within the intestinal wall might be observed at both hypodynamic and resuscitated phases of septic shock ([@B20]). We also observed this apparent dissociation between macro- and microhemodynamics during the resuscitation phase, as has been noted in previous studies ([@B8], [@B30]), but we did not observe discrepancies for serosal-to-mucosal microvascular blood flow distribution during development of shock nor during the resuscitation phase. Effects of dobutamine on villi microcirculation could be mediated by direct adrenergic stimulation ([@B43]), nitric oxide generation ([@B24]), decreased expression of endothelial E-selectin ([@B45]), or inhibition of nuclear factor-κB ([@B25]), although the exact mechanisms through which dobutamine exerted its effect on the microcirculatory blood flow go beyond the scope of our study.

The microcirculatory alterations observed in our experiment were accompanied by increases in jejunal-mucosa and regional mesenteric-to-arterial CO~2~ differences, and these were, in turn, reflected by the accumulation of systemic-venous CO~2~. Interestingly, the grade of recovery of microcirculation was mirrored by decreases in $\text{Pti-}\text{a}_{\text{C}\text{O}_{2}}$ and $\text{Pmes-}\text{a}_{\text{C}\text{O}_{2}}$, suggesting a link between microcirculatory blood flow and tissue or venous CO~2~ accumulation, respectively, as has recently been suggested by observations in human septic shock ([@B31]). Additionally, we observed an increased mesenteric-venous CO~2~-to-arterial venous O~2~ differences ratio ($\text{Pvmes-}\text{a}_{\text{C}\text{O}_{2}}$/$\text{Ca}\text{-vmes}_{\text{O}_{2}}$ ratio) during the development of shock in both experimental groups, evolving in parallel with regional lactate accumulation. Such increased CO~2~-to-O~2~ relationship has been proposed as reflection of anaerobic metabolism, since under aerobic steady-state conditions, CO~2~ production (V̇[co]{.smallcaps}~2~) approximates O~2~ consumption (V̇[o]{.smallcaps}~2~), and, consequently, the mixed venous-to-arterial CO~2~ content difference ($\text{C}\overline{\text{v}}\text{-}\text{a}_{\text{C}\text{O}_{2}}$) approximates the arterial-to-mixed-venous O~2~ content difference ($\text{Ca-}{\overline{\text{v}}}_{\text{O}_{2}}$). Accordingly, the V̇[co]{.smallcaps}~2~-to-V̇[o]{.smallcaps}~2~ ratio (i.e., the respiratory quotient) should not be higher than 1.0, whereby nonsymmetric decreases in V̇[o]{.smallcaps}~2~ and V̇[co]{.smallcaps}~2~ with subsequent rises in the respiratory quotient could reflect nonaerobic CO~2~ generation ([@B30], [@B32]). Importantly, models subjected to dobutamine infusion in our experiment showed a progressive improvement in microvascular blood flow distribution that was in turn related to decreases in the $\text{Pvmes-}\text{a}_{\text{C}\text{O}_{2}}$/$\text{Ca}\text{-vmes}_{\text{O}_{2}}$ ratio (a regional surrogate of the V̇[co]{.smallcaps}~2~/V̇[o]{.smallcaps}~2~ ratio), suggesting the reversal of anaerobic metabolism while mesenteric lactate levels also decreased.

It could be argued that the thermogenic effects induced by dobutamine could explain the increases in the O~2~ extraction ratio in our experiment ([@B15], [@B17]). V̇[o]{.smallcaps}~2~ responses to prostacyclin ([@B6]) and nitroprusside ([@B5]) are, however, quite similar to the responses to dobutamine in septic patients and healthy volunteers ([@B36]). Additionally, the thermogenic effects of catecholamines are related to progressively increased doses, a situation that is avoided when low fixed doses are used (as in our study).

Our model had limitations. First, we focused on microcirculatory blood flow alterations while resuscitation was guided by macrohemodynamic variations, as occurs during resuscitation from human septic shock. Nonetheless, the macrohemodynamics evolved similarly in the dobutamine and placebo groups, suggesting that the effects of dobutamine were mediated at the microcirculatory level. Second, our institutional Animal Research Committee suggested limiting the total number of models, including those used during the preexperimental standardization phase, with the result that we included only three animals in the sham group. Admittedly, some differences were observed in certain macrohemodynamic variables at baseline when comparing the sham animals with the two experimental groups. The inclusion of a higher number of sham models would not, however, have changed our final results, since microcirculatory flow variables were almost identical at baseline in the sham, dobutamine, and placebo groups, whereas macrohemodynamics evolved in parallel in the two experimental groups. Third, our experiment reproduces a severe hypodynamic septic shock, which could distance our results from usual clinical observations. Our model does, however, closely recreate the initial phases of nonresuscitated septic shock with a complete spectrum of enteric pathogens, with immunological and macrohemodynamic disturbances occurring gradually. Fourth, we did not measure variations of arterial mesenteric blood flow, which precludes the analysis of mesenteric-D[o]{.smallcaps}~2~. However, alterations in microvascular blood flow distribution cannot be predicted from macrohemodynamics or even from total microcirculatory flow (i.e., by laser Doppler techniques). Thus, measurements of total microvascular blood flow and its distribution (i.e., estimation of blood flow heterogeneity) could be more, or at least, as relevant as isolated mesenteric arterial blood flow measurements. Furthermore, although indirect, the proportional decrease in mesenteric lactate levels in our experiment provides a strong suggestion that the increase in microvascular perfusion was associated with an improved metabolism associated with better O~2~ utilization.

In conclusion, variations in the heterogeneity of microcirculatory blood flow at the jejunal mucosa are closely linked to regional splanchnic O~2~ extraction ratios and mesenteric lactate levels, thus suggesting a key role for microvascular blood flow distribution on O~2~ utilization in septic shock. Low fixed doses of dobutamine can decrease such flow heterogeneity, promoting O~2~ metabolism recovery.
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Glossary
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COCardiac outputCVPCentral venous pressureD[o]{.smallcaps}~2~Systemic O~2~ deliveryFCDFunctional capillary densityHIHeterogeneity indexLactate-artArterial lactateLactate-mesMesenteric lactateMAPMean arterial pressure$\text{mes-E}\text{R}_{\text{O}_{2}}$Mesenteric O~2~ extraction ratio$\text{P}\text{a}_{\text{CO}}{}_{{}_{2}}$Arterial CO~2~ partial pressure$\text{P}\text{a}_{\text{O}}{}_{{}_{2}}$Arterial O~2~ partial pressurePAOPPulmonary artery occlusion pressurepHArterial pHPPVPercentage of small vessels perfused$\text{Ptis-}\text{a}_{\text{C}\text{O}_{2}}$Tissue (jejunal mucosa)-to-arterial CO~2~ difference$\text{Pti}\text{s}_{\text{C}\text{O}_{2}}$Tissue (jejunal mucosa) CO~2~ pressure$\text{Pv-}\text{a}_{\text{C}\text{O}_{2}}$Mixed venous-to-arterial CO~2~ difference$\text{Pv-}\text{a}_{\text{C}\text{O}_{2}}$/$\text{Da-}\text{v}_{\text{O}_{2}}$Mixed venous-to-arterial CO~2~ to arterial-venous O~2~ pressure differences ratio$\text{Pvmes-}\text{a}_{\text{C}\text{O}_{2}}$Mesenteric venous-to-arterial CO~2~ difference$\text{Pvmes-}\text{a}_{\text{C}\text{O}_{2}}$/$\text{Da-}\text{v}_{\text{O}_{2}}$Mesenteric blood venous-to-arterial CO~2~ to arterial-venous O~2~ pressure difference ratio$\text{Pvme}\text{s}_{\text{C}\text{O}_{2}}$Mesenteric venous CO~2~ partial pressure$\text{Pvme}\text{s}_{\text{O}_{2}}$Mesenteric venous O~2~ partial pressure$\text{Pvm}\text{x}_{\text{O}_{2}}$Mixed-venous O~2~ partial pressure$\text{Pvm}\text{x}_{\text{C}\text{O}_{2}}$Mixed-venous CO~2~ partial pressureSer-FCDFunctional capillary density at jejunal serosaSer-HIHeterogeneity index at jejunal serosaSer-PPVPercentage of small vessels perfused at jejunal serosaSL-FCDFunctional capillary density at sublingual mucosaSL-HIHeterogeneity index at sublingual mucosaSL-PPVPercentage of small vessels perfused at sublingual mucosa$\text{S}\text{v}_{\text{O}_{2}}$Mixed-venous O~2~ saturation$\text{Syst-E}\text{R}_{\text{O}_{2}}$Systemic O~2~ extraction ratioTCDTotal capillary density%Villi-PPVProportion of jejunal-villi with well-perfused vesselsV̇[o]{.smallcaps}~2~Systemic O~2~ consumption
